Gardasil related Press Releases
Kaiser Permanente Study Finds Gardasil does not Trigger Lupus, Rheumatoid Arthritis or Type 1 Diabetes after Vaccination
Kaiser Permanente Study Finds Gardasil does not Trigger Lupus, Rheumatoid Arthritis or Type 1 Diabetes after Vaccination Two-year study tracked results for 190,000 girls and women January 25, 2012 Read more...
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®
GARDASIL now Approved for Prevention of Anal Cancer and AIN WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food Read more...
FDA Advisory Committee Supports Approval of GARDASIL® for Prevention of Anal Cancer and AIN in both Men and Women
FDA Advisory Committee Supports Approval of GARDASIL® for Prevention of Anal Cancer and AIN in both Men and Women WHITEHOUSE STATION, NJ - Nov. 17, 2010 - Merck announced today that the U.S. Food Read more...
PPD to Present at World Vaccine Congress 2010 Conference
WILMINGTON, N.C.--(BUSINESS WIRE)-- PPD, Inc. (Nasdaq: PPDI) today announced Mark Esser, Ph.D., associate director of immunology, and Lisa Kierstead, Ph.D., associate director, labs, will present at Read more...
FDA Advisory Committee Recommends Approval for Use of GARDASIL in Boys and Men
FDA Advisory Committee Recommends Approval for Use of GARDASIL in Boys and Men Committee Agrees that Clinical Data Support the Efficacy and Safety of Merck's GARDASIL in 9- to 26-Year-Old Boys and Read more...
Merck's Gardasil has been updated to include the clinical efficacy and safety of the vaccine for women up to 45 years of age
The product information of Gardasil® has been updated to include the clinical efficacy and safety of the vaccine for women up to 45 years of age Lyon, 9th September 2009 - The product Read more...
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at Conference
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference
Data from an Extension of a Phase II Study
Read more...Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL in Older Women
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45
WHITEHOUSE STATION, N.J., Jan. 9, 2009 -
Read more...Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study Pivotal Study Evaluating Efficacy of GARDASIL in Males in Preventing HPV
Read more...FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers
FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers September 12, 2008 The U.S. Food and Drug Administration today announced the approval of the vaccine Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
